Global Digital Store – Ebooks and Softwares

Tag: Tests

Health Ministry can conduct 16,000 screenings a day by April

PUTRAJAYA: The Health Ministry expects to be able to carry out 16,000 Covid-19 screenings a day by April compared to just 3,500 now.

Health director-general Datuk Dr Noor Hisham Abdullah said that tests are currently being conducted by 18 Health Ministry and five private laboratories.

“The Institute for Medical Research will train several other laboratories, including in military and university hospitals, to enhance Malaysia’s ability to conduct Covid-19 detection tests,” he said at the Covid-19 daily press conference today.

Meanwhile, he said the ministry will deploy more nurses in states with a very high number of Covid-19 patients like at the Sungai Buloh Hospital in Selangor as well as recall retired specialist doctors and nurses.

Other than that, the ministry is also cooperating with private hospitals to jointly tackle the health problem. – Bernama

Read More
https://www.thesundaily.my/local/health-ministry-can-conduct-16000-screenings-a-day-by-april-IN2168684

Views: 0

March 22, 2020
Three Email Tests to Try Today

Here are three email tests to help you start optimizing your program today.

Time of Day: A quick glance of my inbox shows that many senders continue to send weekday mornings. In contrast, most studies on shopping show that most people buy in the evening after work or on weekends. If it?s been a while or you?ve never tested time of day for email sends now is a good time to start testing. Start with general day parts (morning vs. afternoon and morning vs. evening). If you see an uptick for a particular day part, then try expanding testing by breaking that day part down to hourly increments to fine tune.

Read More
http://www.associationofmarketing.org/articles/view.php?article_id=14699

Views: 0

March 16, 2020
Autonomous on-demand buses underway in the streets of Europe

Would you like to take a ride on a driverless bus? This will be possible in five European cities between April and October 2020, where autonomous buses will be tested in real-life traffic conditions. Three international consortia have been awarded with contracts for the final phase of the pre-commercial procurement under the EU-funded FABULOS project. These consortia will pilot autonomous buses as part of the existing public transport systems. The initial tests will run in Gjesdal (Norway), Helsinki (Finland) and Tallinn (Estonia) in the spring and autumn. Pilots will also be launched in Lamia (Greece) and Helmond (the Netherlands).

Read More

Views: 0

March 10, 2020
Boeing factory employee tests positive for virus

US aviation giant Boeing said Monday that one of its factory workers had tested positive for COVID-19, the illness caused by the novel coronavirus—the company’s first known case.

Read More

Views: 0

March 10, 2020
End in sight, but flare-ups likely in the Ebola outbreak in the Democratic Republic of the Congo
Remarks by Dr Ibrahima Socé Fall, World Health Organization Assistant Director-General, Emergency Response

Good afternoon.

I hope that your busy week was interrupted, like mine, with a moment of joy on Tuesday.

That moment was the celebration of a woman being discharged from an Ebola treatment centre in Beni. Her name is Masiko.

She was the last person in the Democratic Republic of the Congo confirmed to have Ebola.

Health workers and other responders sacrificed a lot to get to this point.

Since the outbreak was declared in August 2018 there have been 420 attacks on health facilities in DRC, resulting in 11 deaths and 86 injuries among health care workers and patients.

It’s been a huge amount of work. At the peak of the outbreak, more than 120 cases were being reported each week. 28 health zones were affected, with cases appearing 1200 kilometres apart. In response:
- 11 labs have been set up to test around 3500 samples each week
- 11 Ebola treatment centres were set up to care for people with Ebola
- 300 000 people have been vaccinated
- 250 000 contacts have been registered
- 26 000 safe and dignified burials have been conducted
- More than 3000 health facilities were identified for infection prevention and control support
- More than 1000 metric tonnes of supplies have been delivered
- An Ebola vaccine has been licensed, and two treatments found to be highly effective
- Almost 160 000 million people have been screened for Ebola symptoms at borders or other points of control
This work is continuing. The outbreak isn’t over. WHO recommends waiting two full incubation periods – that’s 42 days – after the last person tests negative a second time before declaring the end of the outbreak.

We must stay in active response mode to get us over that finish line.

We have to be prepared for other cases emerging. It’s is a very real risk.

Remember that during the Ebola outbreak in West Africa flare-ups of new cases occurred after the end of the outbreak.

There are four reasons why new cases may emerge during this 42-day period, or even after the end of the outbreak.
- First, because of the complex security environment, Ebola transmission outside of groups under monitoring is possible.
- Second, Ebola virus can persist in used needles, syringes or vials for several weeks.
- Third, Ebola virus can persist in the body fluids of survivors for many months, and can be transmitted well after recovery, or in rare cases can result in relapse – as we’ve already seen during this outbreak.
- Finally, Ebola virus is present in an animal reservoir in the region, and there is always a risk of a new spillover to humans.
This is why it’s critical to maintain surveillance and rapid response capacities.

And that’s what we are doing. We’re still in full response mode.

In addition to the activities I already mentioned, I have to underline how critical it is to continue supporting the Survivor Programme, which provides follow-up care for almost all of the 1169 survivors in 26 health areas in North Kivu and Ituri. The programme also helps reduce the risks of re-introduction events.

We need to continue this work until the end of the outbreak, to keep the capacity in place to rapidly respond to flare-ups, to keep supporting survivors after the outbreak, and to transition the capacities built in this response toward building a stronger health system.

But to be very frank, right now the world risks dropping the baton at the finish line. WHO faces an immediate US $20 million funding gap. If no new resources are received, we will run out of money before the end of the outbreak.

We appreciate the generosity of donors who have supported the response since August 2018. Now we need to get over the finish line. WHO is calling on the international community to help us end this outbreak, and keep our promises to communities to build a stronger health system.

If we are forced to scale back operations because of a lack of funds, and then a new case emerges, we might not have the people and resources on the ground that we need to shut down transmission quickly. Just a single case could re-ignite the epidemic.

That would be a tragedy. An avoidable tragedy.

It is important that the global community doesn’t only focus efforts when there is an immediate threat, then walk away when the threat subsides.

The health system has to be strong to stop much more than Ebola. It has to stop malaria, measles, cholera, and now COVID-19.

There is a lot more work to do.

Thank you.

Read More
https://www.who.int/news-room/detail/06-03-2020-end-in-sight-but-flare-ups-likely-in-the-ebola-outbreak-in-the-democratic-republic-of-the-congo

Views: 0
March 7, 2020
The unfoldable bridge

There are many different methods for erecting bridges—but the new technique developed by TU Wien, the balanced lowering method, is quite spectacular: the bridge is not built horizontally, as would normally be case, but erected in a vertical position and then rotated into the horizontal position. The first large scale tests were carried out in 2010; since then, the method has been refined and tuned until finally finding its first application by the ASFINAG for two bridges of the Fürstenfeld Motorway S7. With the erection process successfully completed for the Lahnbach Bridge, the 116 m long bridge over the Lafnitz was “unfolded” on the 27th of February 2020. With no scaffolding needed, this new bridge construction method not only saves time but also money and resources.

Read More

Views: 0

March 6, 2020
WHO steps up action to improve access to safe blood
The World Health Organization’s new action plan to speed up universal access to safe blood and blood products pulls together existing recommendations and recommends new improved ways of working. It’s the start of a four-year collaborative effort to improve blood transfusion and blood-based therapies in all countries.

Safe blood saves lives in all sorts of circumstances, not least in emergency and epidemic settings. Blood transfusion and blood products are critical for birth delivery for both the mother and baby; the survival and quality of life of patients suffering from life-threatening conditions such as haemophilia, thalassemia, immune deficiency and cancer; treating severe injuries and carrying out medical and surgical procedures.

But progress in blood safety and availability has been slow in many parts of the world, placing patients’ safety at risk and putting undue pressure on health workers. Progress is also mostly restricted to developed countries. Out of the approximate 118 million blood donations collected globally, 42% are collected in high-income countries, home to 16 % of the world’s population. And one out of four low-income countries do not test all donated blood, while 54% of countries do not have surveillance systems to securitise the supply chain from blood donor to patient.

Challenges include: slow implementation of national blood policies and weak blood regulatory systems; insufficient number of voluntary blood donors (who are considered the safest donors); poor quality management of screening tests, blood grouping and compatibility testing; inappropriate clinical use of blood; insufficient national funding for blood safety.

To address these, WHO has set out six key objectives for all countries and in particular those with weak blood systems:
- appropriately structured, well-coordinated and sustainably resourced national blood systems;
- regulatory capacity to ensure the quality and safety of blood;
- functioning and efficiently managed blood services;
- effective implementation of patient blood management to optimize transfusion practices;
- effective surveillance, haemovigilance and pharmacovigilance, supported by comprehensive and accurate data collection systems;
- partnerships, collaboration and information exchange to achieve key priorities and jointly address challenges and emerging threats at global, regional and national levels.
The Organization looks forward to working with partners worldwide to implement the plan, improve blood supply particularly in the low and middle-income countries where this is so urgently needed, and save lives. The plan will run from 2020-2024.

Read More
https://www.who.int/news-room/detail/26-02-2020-who-steps-up-action-to-improve-access-to-safe-blood

Views: 0
February 27, 2020
Pregnancy and breastfeeding during an Ebola virus outbreak

Women who are pregnant or breastfeeding in an Ebola outbreak face similar challenges as other population groups, but they have specific health needs which must be met.

As the second largest Ebola outbreak in history continues in the Democratic Republic of Congo, WHO has released new clinical guidelines for healthcare providers supporting pregnant or breastfeeding women in the context of Ebola virus disease.

Improving clinical care and reducing mortality

Clear and coherent guidance is needed to meet the combined needs of women requiring Ebola treatment, pregnancy care and management of complications.

Information on how to protect breastfeeding children and other members in the community from transmission of the disease is also critical.

Limited scientific evidence on how to best manage these needs has previously been a challenge for affected countries. In addition, misconceptions that pregnant women have a higher mortality rate than other populations with Ebola may in some contexts have put pregnant women at risk of not receiving standard care.

WHO’s Guideline on the management of pregnant and breastfeeding women in the context of Ebola virus reviews existing evidence and provides a single set of recommendations on the care continuum for women exposed to, diagnosed with, or recovered from Ebola.

This will enable healthcare providers, emergency response teams and health policy-makers to improve prevention and treatment measures in an Ebola outbreak.

Obstetric care at an Ebola Treatment Centre

Optimal supportive care should be offered to all pregnant women with Ebola. Likewise, they should be offered experimental treatment and vaccination under the same conditions as non-pregnant populations.

Ebola virus disease does increase the risk of miscarriage and early labour, requiring close clinical management at Ebola treatment centres. It is important to engage both obstetric providers and those trained in Ebola response.

This dual expertise is also important because early Ebola and pregnancy-related symptoms can overlap. Pregnant women should be prioritised for testing to confirm an Ebola infection.

Ebola virus can persist in pregnancy related fluids as well as breastmilk. If healthcare providers are not clear on how to manage Ebola infection risk, they may be less willing to provide care. This stigma can be life-threatening for women who experience complications during delivery.

The new WHO guidelines advise healthcare workers on how to protect themselves while caring for pregnant women with Ebola virus disease. This includes induced labour or surgical procedures, which carry greater risk of transmission in cases of acute infection. Any invasive treatments should be carried out in full personal protective equipment.

Breastfeeding recommendations in an Ebola outbreak

WHO recommends that women with suspected or confirmed Ebola immediately stop breastfeeding and are prioritised for diagnostic testing. Any child exposed to Ebola through breast milk should be placed into safe care, closely monitored for symptoms over a 21-day period and fed with an appropriate breast milk substitute.

The guidelines strongly recommend that breastfeeding is only restarted following two consecutive negative tests of breast milk, separated by 24 hours.

A breast milk substitute should be used even if infection is confirmed for both the mother and her child. Exceptions can be made for infants under 6 months of age who are already infected, if breast milk substitutes are not feasible, affordable, sustainable or safe and separation cannot be implemented safely.

Women’s health and rights in a disease outbreak

A disease outbreak does not change women’s and adolescent girls’ fundamental human right to sexual and reproductive healthcare, including evidence-based care during pregnancy and childbirth.

Women need support to make informed reproductive health care choices for themselves and their children. Women living in an Ebola outbreak should have access to all relevant reproductive options, regardless of economic, cultural, racial or religious status, including contraception and safe abortion to the full extent of the law.

Pregnant and breastfeeding women across affected communities need equitable and respectful care that considers the risks they face and supports the choices they make.

Accessing the guidelines and further research

These guidelines are now available online and may be freely downloaded. The executive summary will be available in French.

WHO will closely monitor new data as it emerges, as there is still a pressing need to prioritise ongoing research related to Ebola virus transmission.

Read More
https://www.who.int/news-room/detail/10-02-2020-pregnancy-and-breastfeeding-during-an-ebola-virus-outbreak

Views: 0

February 27, 2020
WHO to accelerate research and innovation for new coronavirus

WHO is convening a global research and innovation forum to mobilize international action in response to the new coronavirus (2019-nCoV).

“Harnessing the power of science is critical for bringing this outbreak under control,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “There are questions we need answers to, and tools we need developed as quickly as possible. WHO is playing an important coordinating role by bringing the scientific community together to identify research priorities and accelerate progress.”

The forum, to be held 11-12 February in Geneva, is organized in collaboration with the Global Research Collaboration for Infectious Disease Preparedness.

The forum will bring together key players including leading scientists as well as public health agencies, ministries of health and research funders pursuing 2019-nCoV critical animal health and public health research and the development of vaccines, therapeutics and diagnostics, among other innovations.

Participants will discuss several areas of research, including identifying the source of the virus as well as sharing of biological samples and genetic sequences.

Experts will build on existing SARS and MERS coronavirus research and identify knowledge gaps and research priorities in order to accelerate scientific information and medical products most needed to minimize the impact of the 2019-nCoV outbreak.

The meeting is expected to produce a global research agenda for the new coronavirus, setting priorities and frameworks that can guide which projects are undertaken first. “Understanding the disease, its reservoirs, transmission and clinical severity and then developing effective counter-measures is critical for the control of the outbreak, to reduce deaths and minimize the economic impact,” said Dr. Soumya Swaminathan, WHO Chief Scientist.

This will also fast-track the development and evaluation of effective diagnostic tests, vaccines and medicines, while establishing mechanisms for affordable access to vulnerable populations and facilitating community engagement.

“The WHO R&D Blueprint is a global strategy and preparedness platform that drives coordinated development of drugs and vaccines before epidemics, and allows the rapid activation of R&D activities during epidemics. It speeds up the availability of the diagnostics, vaccines and treatments and technologies that ultimately save lives,” added Dr Michael Ryan, Executive Director, WHO Health Emergencies Programme.

Setting clear global research priorities for the novel coronavirus should lead to more efficient investments, high-quality research and synergies among global researchers.

Read More
https://www.who.int/news-room/detail/06-02-2020-who-to-accelerate-research-and-innovation-for-new-coronavirus

Views: 0

February 27, 2020
E-cigarette vapor does not cause oxidative stress in viable lung epithelial cells

E-cigarette vapour is much less harmful to lung cells than cigarette smoke. Lab tests show that, unlike tobacco smoke, which causes oxidative stress and cell death, e-cigarette vapour does not. Oxidative stress and cell death are driving factors in the development of many smoking-related diseases such as COPD and lung cancer.

Vapour from e-cigarettes has been found to contain significantly lower levels of the toxicants found in cigarette smoke (Chemical Research in Toxicology DOI: 10.1021/acs.chemrestox.6b00188), but suitable lab tests and clinical studies are necessary to understand whether this translates into reductions in biological responses and disease.

Researchers at British American Tobacco have developed a standardized way of measuring and comparing the potential of conventional cigarette smoke and e-cigarette vapour to cause oxidative stress in an in vitro model of lung epithelium.

Views: 0

February 27, 2020